New publication📝Data from PSoHO, published in Dermatology and Therapy, show anti-IL-17A biologics achieved superior PASI100 durability vs other classes over 24 months in patients with moderate-to-severe psoriasis. Learn more: https://loom.ly/blzr6r8 #Psoriasis #PsO #MedNews #MedEd
About us
The Psoriasis and Psoriatic Arthritis Hub (PsOPsA Hub) is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in psoriasis and psoriatic arthritis. Our aim is to enhance knowledge in psoriasis and psoriatic arthritis through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management. The Psoriasis and Psoriatic Arthritis Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
- Website
-
https://psoriasis-hub.com/
External link for PsOPsA Hub
- Industry
- E-Learning Providers
- Company size
- 11-50 employees
- Type
- Privately Held
Employees at PsOPsA Hub
Updates
-
Thank you to our funder, UCB, who makes it possible for us to deliver the PsOPsA Hub. #Psoriasis #PsoriaticArthritis
-
-
🚨 NEWS 🚨 The European Commission approves guselkumab for children and adolescents aged ≥6 years with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Read more: https://loom.ly/WH-m204 #psoriasis #MedEd #MedNews
-
-
🚨 News 🚨 The EMA CHMP has adopted a positive opinion on an ustekinumab biosimilar auto-injector (as 45 mg/0.5 mL and 90 mg/1 mL solutions), including for the treatment of plaque #psoriasis and #PsoriaticArthritis. 👉 https://loom.ly/qIzs7vE #MedNews #MedEd #PsO #PsA
-
-
🚨News🚨 Health Canada has approved a topical cream containing 0.05 mg/g calcipotriol and 0.5 mg/g betamethasone dipropionate for the treatment of psoriasis vulgaris in adults and adolescents aged 12–17 years, for use up to 8 weeks. 👉https://loom.ly/HnWrY5c #MedNews #MedEd #psoriasis
-
-
New publication 📝 Phase II ARGO trial results, published in Nature Medicine, show a higher proportion of patients with active PsA achieved ACR50 at Week 12 with sonelokimab 60 mg (46.3%; p < 0.05) and 120 mg WI (46.5%; p < 0.01) groups compared with placebo (20.0%). Learn more: https://loom.ly/XyS-QRc #PsA #MedNews #MedEd
-
-
New publication 📝 A post hoc analysis of phase III/IIIb trials, published in Dermatology and Therapy, shows bimekizumab demonstrated consistently high long-term efficacy in patients with plaque psoriasis across diverse subgroups. Learn more: https://loom.ly/zcCeABk #PsO #MedNews #MedEd
-
-
New data 📝 Phase III POETYK PsA-1 and PsA-2 pooled analyses, presented at #ACR25, found a higher proportion of patients with #PsoriaticArthritis treated with deucravacitinib vs placebo achieved improvements in global disease activity. Learn more: https://loom.ly/XyS-QRc #PsA #MedNews #MedEd
-
-
New data 📝 Phase III ICONIC-LEAD subgroup analyses, presented at #ACR25, show icotrokinra maintained responses at Week 24: IGA 0/1 (86.4%) and PASI 90 (88.6%) in adolescents with moderate-to-severe plaque #psoriasis. Learn more about plaque psoriasis: https://loom.ly/zcCeABk #MedNews #MedEd
-
-
New data 📝 A real-world study, presented at #EADVCongress 2025, shows lower baseline PASI, absence of palmoplantar involvement, and being biologic-naïve predict early super response to bimekizumab in patients with #psoriasis. Learn more: https://loom.ly/zcCeABk #PsO #MedNews #MedEd
-